Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Patients with persistent or recurrent epithelial ovarian cancer, peritoneal cancer,
or fallopian tube cancer

- Platinum-resistant (less than 6 months from date of last platinum therapy to
date of first evidence of recurrent or persistent disease) disease as measured
by any of the following:

- Imaging

- Physical exam

- CA-125 that is twice the upper limit of normal on two occasions with at
least one week apart

- No patients who have platinum resistant or refractory disease after more than 6
months since prior therapy

- Criteria for patients on cancer therapy (e.g., chemotherapy, non-cytotoxic regimens,
hormone therapy, or radiation therapy) include recurrent or persistent disease
defined as having measurable disease per RECIST (Version 1.1)

- Patients not on chemotherapy are also eligible and are not required to have
RECIST criteria

PATIENT CHARACTERISTICS:

- Life expectancy of at least 6 months

- Patients with any performance status, yet with the ability to verbally consent and
participate in the first assessment

- Study measures will be administered in the office/clinic setting, or for study
participants who are unable to attend clinics, via telephone or mail (telephone
is the preferred back-up means)

- Patients may have or have had a prior non-gynecologic malignancy within 5 years prior
to study enrollment; however, they must have completed all treatments for the disease
and have no evidence of disease at the time of enrollment, and ovarian, peritoneal,
or fallopian tube cancer must be the primary life-threatening diagnosis

- Patient must be able to read and write English

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No patients receiving chemotherapy for platinum-sensitive ovarian cancer, peritoneal,
or fallopian tube cancer